A phase I/Ib study of concurrent intravenous (IV) and intrathecal (IT) nivolumab (Nivo) for melanoma patients (pts) with leptomeningeal disease (LMD)

被引：0
|
作者：
Glitza, I. C. [1 ]
Rohlfs, M. L. [1 ]
Iqbal, M. [1 ]
Richard, J. [1 ]
Burton, E. [1 ]
Duncan, S. [1 ]
Brown, C. [1 ]
Anderson, J. [1 ]
Hwu, P. [1 ]
Hwu, W-J. [1 ]
Wong, M. [1 ]
Yee, C. [1 ]
Patel, S. [1 ]
Woodman, S. [1 ]
Amaria, R. [1 ]
Diab, A. [1 ]
Tawbi, H. [1 ]
Davies, M. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Melanoma Med Oncol, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1301TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase 1b study of TAK-659+nivolumab (nivo) in patients (pts) with advanced solid tumors.
    Juric, Dejan
    Olszanski, Anthony J.
    Vaishampayan, Ulka N.
    Li, Cong
    Wang, Shining
    Shou, Yaping
    Rong, Yuanxin
    Nemunaitis, John
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma.
    Lau, Peter Kar Han
    Harris, Samuel John
    Eastgate, Melissa A.
    Kee, Damien
    Mant, Andrew
    Nott, Louise M.
    Gedye, Craig
    Inderjeeth, Andrisha Jade
    Underhill, Craig
    Weppler, Alison Margaret
    Wallace, Roslyn
    Lee, Belinda
    Au-Yeung, George
    Williams, Narelle
    Ospino, Daniel Ariza
    Gonzales, Louise
    Shackleton, Mark J.
    Lo, Serigne N.
    McArthur, Grant A.
    Sandhu, Shahneen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients (pts) with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Updated efficacy and safety results from CheckMate 67T
    Albiges, L.
    Bourlon de los Rios, M. T.
    Chacon, M.
    Cutuli, H. J.
    Lopez Chuken, Y. A.
    Mota, J.
    Magri, I.
    Burotto, M.
    Luz, M. D. A.
    Menezes, J.
    Yanez Ruiz, E. P.
    Maruzzo, M.
    Bracarda, S.
    Breckenridge, M.
    Rathod, D.
    Yu, Z.
    Vezina, H.
    George, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S1013 - S1014
  • [34] Phase I study of nivolumab combined with IFN-β for patients with advanced melanoma
    Fujimura, Taku
    Hidaka, Takanori
    Kambayashi, Yumi
    Furudate, Sadanori
    Kakizaki, Aya
    Tono, Hisayuki
    Tsukada, Akira
    Haga, Takahiro
    Hashimoto, Akira
    Morimoto, Ryo
    Yamaguchi, Takuhiro
    Takano, Tadao
    Aiba, Setsuya
    ONCOTARGET, 2017, 8 (41) : 71181 - 71187
  • [35] Phase I/IB trial of sitravatinib (Sitra) plus nivolumab (Nivo) plus ipilimumab (Ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC) or other solid malignancies.
    Msaouel, Pavlos
    Gao, Jianjun
    Yuan, Ying
    Siefker-Radtke, Arlene O.
    Jonasch, Eric
    Goswami, Sangeeta
    Zurita, Amado J.
    Campbell, Matthew T.
    Shah, Amishi Yogesh
    Corn, Paul G.
    Ramos, Claudia
    Yan, Xiaohong
    Chin, Curtis
    Der-Torossian, Hirak
    Tannir, Nizar M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [36] Phase II study of nivolumab (nivo) with relatlimab (rela) in patients (pts) with first-line advanced melanoma: Early on-treatment major pathologic response on biopsy.
    Karapetyan, Lilit
    Karunamurthy, Arivarasan
    Cillo, Anthony
    Rohatgi, Anjali
    Massa, Ryan Campbell
    Gooding, William E.
    Najjar, Yana G.
    Davar, Diwakar
    Luke, Jason J.
    Bruno, Tullia C.
    Vignali, Dario
    Kirkwood, John M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [37] A phase Ib study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 117
    Kudo, Masatoshi
    Ikeda, Masafumi
    Motomura, Kenta
    Okusaka, Takuji
    Kato, Naoya
    Dutcus, Corina E.
    Hisai, Takashi
    Suzuki, Mayumi
    Ikezawa, Hiroki
    Iwata, Takeyuki
    Kumada, Hiromitsu
    Kobayashi, Masahiro
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [38] Phase I/II study of axitinib (axi) and nivolumab (nivo) in patients with metastatic renal cell carcinoma (mRCC).
    Zibelman, Matthew R.
    Geynisman, Daniel M.
    Molina, Ana M.
    Malizzia, Lois
    Devarajan, Karthik
    Luong, Diana
    Sullivan, Elizabeth
    Carducci, Michael Anthony
    Plimack, Elizabeth R.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [39] PHASE IB/II STUDY OF NIVOLUMAB IN COMBINATION WITH AZACYTIDINE (AZA) IN PATIENTS (PTS) WITH RELAPSED ACUTE MYELOID LEUKEMIA (AML)
    Daver, N.
    Basu, S.
    Garcia-Manero, G.
    Cortes, J.
    Ravandi, F.
    Jabbour, E.
    Pemmaraju, N.
    Hendrickson, S.
    Gordon, T.
    Brandt, M.
    Pierce, S.
    Matthews, J.
    Kornblau, S.
    Flores, W.
    Konopleva, M.
    Kantarjian, H.
    Sharma, P.
    HAEMATOLOGICA, 2017, 102 : 176 - 177
  • [40] Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511)
    Lebbe, C.
    Meyer, N.
    Mortier, L.
    Marquez-Rodas, I.
    Robert, C.
    Rutkowski, P.
    Menzies, A. M.
    Eigentler, T.
    Ascierto, P. A.
    Smylie, M.
    Ajaz, M.
    Svane, I-M.
    Gonzalez, R.
    Rollin, L.
    Saci, A.
    Grigoryeva, E.
    Pigozzo, J.
    ANNALS OF ONCOLOGY, 2018, 29 : 737 - 737
12345